KRRO is in the biotechnology space in the gene-editing realm. It is in portfolios of C. Woods . A recent analyst gave it an upside to 100 which is very favorable given its product line and track record with an all-time high of about $250 ( which is about 450% over current valuation) On the one-hour time frame, it has had a great week and is breaking out over...
RNA Therapeutics Leadership: Avidity Biosciences NASDAQ:RNA is at the forefront of RNA therapeutics with its innovative antibody-oligonucleotide conjugates (AOCs). Its lead candidate, Del-desiran (AOC 1001), targeting myotonic dystrophy type 1, is on the verge of a pivotal trial. Approval could significantly boost earnings. Strategic Partnership: Avidity's...
BNTC Benitec Biopharma Inc is a development-stage biotechnology company which focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics. BlackRock Inc., Renaissance Technologies LLC, Vanguard Group Inc. and Morgan Stanley have stakes in it. On 2/17/2022 P. Trucchio from HC Wainwright brokerage...
BTC Benitec Biopharma is sitting now at a key support from which we can expect a bounce. We know that earlier this year they had a 7.5mil offering price to the public of $4.25 per share and that Morgan Stanley has a 5.2% stake in the genetic drug company. Benitec's "proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA...
A little intro to the biotech cycle... It could be real big. RNA technology can do a little bit more than tell your genes to produce spike protein. It could be used to fight cancer. It could also be used to increase life expectancy from 75 years to perhaps 90. And more importantly, make people age slower as well as kill "deficient" cells involved in aging. This...
#CRSP CRSP NASDAQ:CVAC SWB:8EM